Scarica l'app Stockscreener
22.70
4.64%
1.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.68
Aprire:
$21.34
Volume 24 ore:
257.22K
Relative Volume:
0.10
Capitalizzazione di mercato:
$282.20M
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-15.55
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-9.25%
1M Prestazione:
-7.74%
6M Prestazione:
+2,642%
1 anno Prestazione:
+1,686%
Intervallo 1D:
$21.02
$22.99
Intervallo di 1 settimana:
$21.02
$25.50
Portata 52W:
$0.432
$37.38
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
22.75 | 381.82M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.26 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.38 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.91 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
679.38 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.85 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
What is the dividend policy of Nektar Therapeutics stockChart Pattern Picks With Low Risk - jammulinksnews.com
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets - WV News
Nektar soars on atopic dermatitis data, leads drug developer gainers in Q2 - BioWorld MedTech
What are analysts’ price targets for Nektar Therapeutics in the next 12 monthsAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
Signal strength of Nektar Therapeutics stock in tech scannersSmart Trade Plans With Risk Protection Explained - metal.it
Phase 2b Repibresib Study Falls Short of Key Goals - Dermatology Times
What makes Nektar Therapeutics stock price move sharplyEntry and Exit Strategy Optimizer Tool Tested - metal.it
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata - Eastern Progress
Nektar gets FDA fast track status for alopecia areata drug - Seeking Alpha
FDA Grants Fast Track Designation to Nektar's Rezpegaldesleukin in Alopecia Areata - Dermatology Times
Nektar receives FDA fast track for alopecia areata treatment - StreetInsider
Nektar Therapeutics to Host Earnings Call - ACCESS Newswire
Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin - Insider Monkey
What institutional investors are buying Nektar Therapeutics stockStock Strategy Trend Scanner To Watch Now - jammulinksnews.com
Should I hold or sell Nektar Therapeutics stock in 2025Capitalize on fast-moving stock trends - jammulinksnews.com
How does Nektar Therapeutics compare to its industry peersUnlock powerful stock screening for profits - jammulinksnews.com
What are Nektar Therapeutics company’s key revenue driversFree Investment Case Studies - jammulinksnews.com
What is Nektar Therapeutics company’s growth strategyAchieve consistent high returns with low risk - jammulinksnews.com
How many analysts rate Nektar Therapeutics as a “Buy”Capitalize on market momentum for maximum gains - jammulinksnews.com
Why Nektar Therapeutics stock attracts strong analyst attentionReturn Optimized Trade Insights - metal.it
Is Nektar Therapeutics a good long term investmentDynamic capital growth - PrintWeekIndia
What drives Nektar Therapeutics stock priceFree Daily Trading Room Entry - Autocar Professional
What analysts say about Nektar Therapeutics stockTriple-digit growth rates - Autocar Professional
Nektar Therapeutics's Options: A Look at What the Big Money is Thinking - Nasdaq
Nektar Therapeutics Stock Analysis and ForecastStrong return on investment - jammulinksnews.com
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam - MSN
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
May 19 '25 |
Sale |
0.67 |
9,996 |
6,697 |
314,296 |
| ROBIN HOWARD W | President & CEO |
May 19 '25 |
Sale |
0.67 |
23,208 |
15,549 |
1,063,693 |
0.14%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):